|
FDA approves GSK's Arnuity Ellipta to treat asthma in US
Pharmaceutical Business Review The US Food and Drug Administration (FDA) has approved GlaxoSmithKline's (GSK) fluticasone furoate inhalation powder, to be sold as Arnuity Ellipta, as a daily-once corticosteroid for treatment of asthma in patients aged above twelve years in the US. |
View full post on asthma – Google News